| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 09/08/2004 | CN1526400A Tubiflorous desert cistanche prepn containing phenethyl alcohol glycoside and its prepn process and use |
| 09/08/2004 | CN1165550C Synthetic polysaccharides, their method of prodn. and pharmaceutical compositions contg. same |
| 09/08/2004 | CN1165536C Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 09/08/2004 | CN1165522C Bradykinin receptor antagonists |
| 09/08/2004 | CN1165518C Biocyclic amino acids compound compound as pharmaceutical agents |
| 09/08/2004 | CN1165339C Pharmaceutical compositions of erythropoietin |
| 09/07/2004 | US6787521 Skin disorders; kidney and liver disorders |
| 09/07/2004 | CA2093770C Aspartic acid derivatives, their preparation and use |
| 09/02/2004 | WO2004074215A1 Process for preparation of clopidogrel, its salts and pharmaceutical compositions |
| 09/02/2004 | WO2004073733A1 Interleukin 6 production inhibitor |
| 09/02/2004 | WO2004073725A1 Active ingredients preparation and single compound purification from traditional chinese herbal medicine fructus trichosanthis and uses thereof |
| 09/02/2004 | WO2004073706A1 Drug for reducing side effects in ribavirin interferon combination therapy |
| 09/02/2004 | WO2004073699A1 Pharmaceuticals comprising shikonins as active constituent |
| 09/02/2004 | WO2004073588A2 Diagnostics and therapeutics for diseases associated with g protein coupled receptor r35 (r35) |
| 09/02/2004 | WO2004062551A3 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
| 09/02/2004 | US20040171839 Serine protease inhibitor; therapy for thrombosis , cardiovascular disorders |
| 09/02/2004 | US20040171830 Carboline derivatives as pdev inhibitors |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171664 Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event |
| 09/02/2004 | US20040171658 Blood coagulation factor Xa inhibition; such as 2-O-(3'-amidinobenzyl)-5-O-(3''-amidinophenyl)-1,4:3,6-dianhydrosorbitol |
| 09/02/2004 | US20040171618 Compounds as PDE IV and TNF-inhibitors |
| 09/02/2004 | US20040171617 treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer |
| 09/02/2004 | US20040171616 preventing and treating thrombotic conditions, such as coronary artery disease, cerebrovascular disease, and other coagulation related disorders |
| 09/02/2004 | US20040171592 reduced gastric effects; salicylic acid derivatives |
| 09/02/2004 | US20040171579 anticoagulant piscine glucosaminoglycans; coating agent for invasive medical equipment |
| 09/02/2004 | US20040171538 Anticoagulants and their uses |
| 09/02/2004 | US20040171530 Polypeptides containing cysteine and tryptophan |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171111 Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170712 Applying a Jojoba oil extruded from Jojoba seeds |
| 09/02/2004 | US20040170711 Medical effect of Jojoba oil in the treatment of anal diseases |
| 09/02/2004 | US20040170710 Treating vaginal diseases by applying Jojoba oil extruded from Jojoba seeds |
| 09/02/2004 | US20040170649 uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact; autologous vaccines |
| 09/02/2004 | US20040170624 active principle, especially the humanized monoclonal antibody JAQ1, that induces irreversible inactivation or degradation of the collagen receptor on thrombocytes; diagnostic agent for the determination of the expression rate of the collagen receptor GPVI |
| 09/02/2004 | US20040170620 Selected antibody compositions for binding to aminophospholipids |
| 09/02/2004 | US20040170618 antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. |
| 09/02/2004 | US20040170610 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 09/02/2004 | CA2833559A1 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/01/2004 | EP1452546A2 Poly-beta-1,4-N-Acetyglucosamine |
| 09/01/2004 | EP1451369A2 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201 |
| 09/01/2004 | EP1451364A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 09/01/2004 | EP1451315A2 Human coagulation factor vii polypeptides |
| 09/01/2004 | EP1451308A2 Therapeutic use of aziridino compounds |
| 09/01/2004 | EP1451303A1 Detection of haematopoietic stem cells and progeny and uses thereof |
| 09/01/2004 | EP1451222A2 Novel proteins with il-6 inhibiting activity |
| 09/01/2004 | EP1451210A2 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451191A1 Thioether substituted imidazoquinolines |
| 09/01/2004 | EP1451187A1 Amide substituted imidazopyridines |
| 09/01/2004 | EP1451186A2 Urea substituted imidazopyridines |
| 09/01/2004 | EP1451185A1 Indole-2-carboxamides as factor xa inhibitors |
| 09/01/2004 | EP1451175A1 Thrombin inhibitors |
| 09/01/2004 | EP1451165A1 Substituted benzoxazoles and analogues as estrogenic agents |
| 09/01/2004 | EP1451151A1 Hydroperylene derivatives |
| 09/01/2004 | EP1450892A2 Manual processing systems and methods for providing blood components conditioned for pathogen inactivation |
| 09/01/2004 | EP1450842A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 09/01/2004 | EP1450829A1 Storage-stable fibrinogen solutions |
| 09/01/2004 | EP1450811A2 2-aryl pyrrolopyrimidines for a1 and a3 receptors |
| 09/01/2004 | EP1450801A2 2-aminoquinoline compounds |
| 09/01/2004 | EP1450800A2 SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS |
| 09/01/2004 | EP1450788A1 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema |
| 09/01/2004 | EP1450779A1 Method for treating autoimmune diseases |
| 09/01/2004 | EP1450769A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 09/01/2004 | EP1450666A2 Methods and compositions to treat cardiovascular disease using 139,258,1261,1486,2398,2414,7660,8587,10183,10550,12680,17921,32248,60489 or 93804 |
| 09/01/2004 | EP1274675B1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
| 09/01/2004 | EP1037529A4 Composition useful for providing one-step surgical preparation and drape |
| 09/01/2004 | EP0923530B1 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
| 09/01/2004 | EP0880502B1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents |
| 09/01/2004 | CN1526261A Mounting arrangement for auxiliary burner or lance |
| 09/01/2004 | CN1525978A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/01/2004 | CN1525977A Purification of human serum albumin |
| 09/01/2004 | CN1525966A New compounds, which are potent inhibitors of Na<+>/Ca<2+> exchange mechanism and are useful in the treatment of arrhythmias |
| 09/01/2004 | CN1525956A Alpha -amino-n-hydroxy-acetamide derivatives |
| 09/01/2004 | CN1525955A Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 09/01/2004 | CN1525867A Pharmaceutically stable hemostatic compositions |
| 09/01/2004 | CN1524534A Polysaccharide sulphate for injection and its preparing process |
| 09/01/2004 | CN1524529A Pharmaceutical preparation and processe for platelet aggregation |
| 09/01/2004 | CN1524521A Troxerutin for injection and method for preparing the same |
| 09/01/2004 | CN1164744C Preparing process of modification enzyme for earthworm fibrinolysin |
| 09/01/2004 | CN1164579C Thiazole and oxazole derivatives and their pharmaceutical use |
| 09/01/2004 | CN1164329C Thrombase capable of carrying about and its preparation method |
| 09/01/2004 | CN1164316C Capsule for treating leucopenia disease and its preparation method |
| 09/01/2004 | CN1164289C Compound gingko leaf preparation and its making process |
| 09/01/2004 | CN1164285C Medicine for treating primary thrombocytopenia purpura |
| 09/01/2004 | CN1164272C Comoposition containing ligustrazine, penetrating skin paste agent of igustrazine and its preparation method |
| 08/31/2004 | US6784195 Extracellular signal regulated kinase (erk); anticancer agents and protein kinase inhibitors |
| 08/31/2004 | US6784191 As blood-coagulation inhibitor or an agent for therapy and prophylaxis of thrombosis or embolism, containing |
| 08/31/2004 | US6784182 Serine protease inhibitors |
| 08/31/2004 | US6784174 Inhibitors of the production of cytokines such as tnf |
| 08/31/2004 | US6783977 Internal ribosome entry site and vector containing same |
| 08/31/2004 | US6783960 Polypeptide for use in the treatment of thrombosis and sepsis |
| 08/26/2004 | WO2004072643A2 Diagnostics and therapeutics for diseases associated with glucagon-like peptide 2 receptor (glp2r) |
| 08/26/2004 | WO2004071532A1 Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses |
| 08/26/2004 | WO2004071531A1 Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| 08/26/2004 | WO2004071523A1 Stem cell factor for preventing chemotherapy-induced depletion of blood cells |
| 08/26/2004 | WO2004071395A2 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox1r (ox1r) |
| 08/26/2004 | WO2004071392A2 Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) |
| 08/26/2004 | WO2004071378A2 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 08/26/2004 | WO2003092602A3 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |